JP2013534805A5 - - Google Patents

Info

Publication number

JP2013534805A5

JP2013534805A5 JP2013508228A JP2013508228A JP2013534805A5 JP 2013534805 A5 JP2013534805 A5 JP 2013534805A5 JP 2013508228 A JP2013508228 A JP 2013508228A JP 2013508228 A JP2013508228 A JP 2013508228A JP 2013534805 A5 JP2013534805 A5 JP 2013534805A5

Authority

JP

Japan

Prior art keywords

aars

polypeptide

item

cell

tables

Prior art date

2011-04-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 claims description 215
• 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 claims description 215
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 97
• 229920001184 polypeptide Polymers 0.000 claims description 94
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 94
• 239000000203 mixture Substances 0.000 claims description 73
• 108090000623 proteins and genes Proteins 0.000 claims description 65
• 102000004169 proteins and genes Human genes 0.000 claims description 61
• 210000004027 cell Anatomy 0.000 claims description 56
• 230000027455 binding Effects 0.000 claims description 36
• 230000000694 effects Effects 0.000 claims description 36
• 108091033319 polynucleotide Proteins 0.000 claims description 35
• 102000040430 polynucleotide Human genes 0.000 claims description 35
• 239000002157 polynucleotide Substances 0.000 claims description 35
• 150000001875 compounds Chemical class 0.000 claims description 32
• 238000000034 method Methods 0.000 claims description 31
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
• 150000001413 amino acids Chemical class 0.000 claims description 21
• 230000001225 therapeutic effect Effects 0.000 claims description 19
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
• 239000011230 binding agent Substances 0.000 claims description 12
• 201000010099 disease Diseases 0.000 claims description 11
• 108010001857 Cell Surface Receptors Proteins 0.000 claims description 10
• 102000006240 membrane receptors Human genes 0.000 claims description 10
• 239000002773 nucleotide Substances 0.000 claims description 9
• 125000003729 nucleotide group Chemical group 0.000 claims description 9
• 102000004190 Enzymes Human genes 0.000 claims description 8
• 108090000790 Enzymes Proteins 0.000 claims description 8
• 238000004519 manufacturing process Methods 0.000 claims description 8
• 239000008194 pharmaceutical composition Substances 0.000 claims description 8
• 239000000126 substance Substances 0.000 claims description 8
• 239000002158 endotoxin Substances 0.000 claims description 7
• 238000012360 testing method Methods 0.000 claims description 7
• 108091034117 Oligonucleotide Proteins 0.000 claims description 6
• 102000039446 nucleic acids Human genes 0.000 claims description 6
• 108020004707 nucleic acids Proteins 0.000 claims description 6
• 150000007523 nucleic acids Chemical class 0.000 claims description 6
• 230000002797 proteolythic effect Effects 0.000 claims description 5
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 4
• 230000001413 cellular effect Effects 0.000 claims description 4
• 230000000295 complement effect Effects 0.000 claims description 4
• 208000035475 disorder Diseases 0.000 claims description 4
• 230000008482 dysregulation Effects 0.000 claims description 4
• 208000027866 inflammatory disease Diseases 0.000 claims description 4
• 230000001404 mediated effect Effects 0.000 claims description 4
• 206010028980 Neoplasm Diseases 0.000 claims description 3
• 201000011510 cancer Diseases 0.000 claims description 3
• 206010012601 diabetes mellitus Diseases 0.000 claims description 3
• 201000001119 neuropathy Diseases 0.000 claims description 3
• 230000007823 neuropathy Effects 0.000 claims description 3
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
• 102000005962 receptors Human genes 0.000 claims description 3
• 239000012679 serum free medium Substances 0.000 claims description 3
• 230000015572 biosynthetic process Effects 0.000 claims description 2
• 238000012217 deletion Methods 0.000 claims description 2
• 230000037430 deletion Effects 0.000 claims description 2
• 238000001514 detection method Methods 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 230000003993 interaction Effects 0.000 claims description 2
• 230000001766 physiological effect Effects 0.000 claims description 2
• 239000007787 solid Substances 0.000 claims description 2
• 238000006467 substitution reaction Methods 0.000 claims description 2
• 239000000758 substrate Substances 0.000 claims description 2
• 238000003786 synthesis reaction Methods 0.000 claims description 2
• 239000003814 drug Substances 0.000 claims 4
• 230000001747 exhibiting effect Effects 0.000 claims 1
• 239000002609 medium Substances 0.000 claims 1
• 239000012634 fragment Substances 0.000 description 80
• 108020001507 fusion proteins Proteins 0.000 description 12
• 102000037865 fusion proteins Human genes 0.000 description 12
• 239000000523 sample Substances 0.000 description 12
• 230000004071 biological effect Effects 0.000 description 8
• 230000033228 biological regulation Effects 0.000 description 8
• 125000000266 alpha-aminoacyl group Chemical group 0.000 description 6
• 239000012528 membrane Substances 0.000 description 5
• 238000000746 purification Methods 0.000 description 5
• 238000005556 structure-activity relationship Methods 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 230000035897 transcription Effects 0.000 description 4
• 238000013518 transcription Methods 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 3
• 108010076504 Protein Sorting Signals Proteins 0.000 description 3
• 230000002776 aggregation Effects 0.000 description 3
• 238000004220 aggregation Methods 0.000 description 3
• 102000003675 cytokine receptors Human genes 0.000 description 3
• 108010057085 cytokine receptors Proteins 0.000 description 3
• 230000004054 inflammatory process Effects 0.000 description 3
• 230000005945 translocation Effects 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 230000033115 angiogenesis Effects 0.000 description 2
• 238000004166 bioassay Methods 0.000 description 2
• 238000000423 cell based assay Methods 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 230000008622 extracellular signaling Effects 0.000 description 2
• 230000009368 gene silencing by RNA Effects 0.000 description 2
• 102000034356 gene-regulatory proteins Human genes 0.000 description 2
• 108091006104 gene-regulatory proteins Proteins 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 230000009703 regulation of cell differentiation Effects 0.000 description 2
• 230000025053 regulation of cell proliferation Effects 0.000 description 2
• 230000024833 regulation of cytokine production Effects 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• 229920003169 water-soluble polymer Polymers 0.000 description 2
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 208000029578 Muscle disease Diseases 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 230000011712 cell development Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 239000003795 chemical substances by application Substances 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 239000013068 control sample Substances 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 208000016097 disease of metabolism Diseases 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 238000002493 microarray Methods 0.000 description 1
• 108091005573 modified proteins Proteins 0.000 description 1
• 102000035118 modified proteins Human genes 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 239000000816 peptidomimetic Substances 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 210000000229 preadipocyte Anatomy 0.000 description 1
• 239000013615 primer Substances 0.000 description 1
• 239000002987 primer (paints) Substances 0.000 description 1
• 238000010377 protein imaging Methods 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 210000002363 skeletal muscle cell Anatomy 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1